Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.84 |
| ▸ | TSHR | P16473 | 2/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16177 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TDP1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL33449 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TDP1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL2418469 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TDP1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL24551 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TDP1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL16774769 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TDP1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL261591 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TDP1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL111093 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TDP1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL262456 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TDP1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL38145 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TDP1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL12977796 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TDP1SMN1; SMN2TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120253032-A1 | NOVEL CATIONIC LIPIDS WITH SHORT LIPID CHAINS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORPORATION | 2012-10-04 | — | — | US | disclosed |
| US-5190969-A | Epoxy derivatives of amino acids as viricides for treatment of HIV infections | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 1993-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120253032-A1 | NOVEL CATIONIC LIPIDS WITH SHORT LIPID CHAINS FOR OLIGONUCLEOTIDE DELIVERY | NPC1L1, LDLR, NPC1 | ALDH1A1 4810/4885TDP1 4728/4885SMN1; SMN2 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.